ArticleDigestive diseases and sciences2026
Low-Dose Naltrexone in Crohn's Disease: A Prematurely Terminated Randomized Trial Showing Reduced Fatigue Without Clinical or Endoscopic Benefit.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCrohn's disease (CD) is often refractory to standard therapies, and patients are sometimes reluctant to initiate immunosuppressive therapy, prompting interest in novel treatments such as low-dose naltrexone (LDN).
aimsTo evaluate the efficacy of LDN for induction of remission in patients with mild-to-moderate active CD.
methodsWe conducted a multicenter, double-blind, placebo-controlled trial in 7 hospitals in the Netherlands. Adults with active CD (defined by mucosal ulcers on endoscopy and Simple endoscopic score for CD 3-15) were randomized 1:1 to LDN 4.5 mg once daily or placebo for 12 weeks. The primary endpoint was endoscopic remission at week 12. Secondary endpoints included clinical and endoscopic response, safety and patient-reported outcome measures. The trial was stopped early due to futility.
resultsForty-one patients were randomized. After 12 weeks, endoscopic remission occurred in 1 (5.6%) vs. 3 (18.8%) patients for LDN and placebo (p=0.233), respectively. Clinical remission occurred in 22.2% (LDN) vs. 70.0% (placebo) (p=0.037). No serious adverse events were reported. For the FACIT-Fatigue questionnaire, the median difference after 12 weeks was 2.5 (IQR 0-7) for LDN vs. -3 (IQR -7-2) for placebo (p=0.012). Additionally, patient-reported outcomes showed no significant difference between LDN and placebo.
conclusionsLDN was not effective for inducing remission in CD and showed no benefit over placebo. Despite not being an effective treatment for clinical and endoscopic outcomes, it may enhance better quality of life by reducing fatigue symptoms. Future studies are needed to clarify its potential benefit on fatigue in patients with inflammatory bowel disease.
Indexed as
Identifiers
42701992What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.